We have been using Onyx, a non-adhesive liquid polymer, to treat cerebral AVMs endovascularly since 1999. During this time we have treated 45 consecutive, unselected patients. From the outset this product brought about a change in our approach to treating this type of lesion because of the different injection behaviour observed for this material compared with the adhesive Histoacryl that had been employed until then. The object of this article is to assess the results achieved by our team using this new embolic agent, following angiographic and clinical follow- up of cases for a minimum of six months and a maximum of five years (mean: two years). We propose new categories of cerebral AVM based on the expected behaviour of Onyx within the nidus. Our appraisal indicates that we have improved our angiographic results, achieving complete occlusion of the malformation in 22% of cases and over 80-% closure in 69% of cases. The morbimortality rate for the procedure was 18%.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404756 | PMC |
| http://dx.doi.org/10.1177/15910199050110S118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-operative hemorrhage in patients with aneurysms associated with arteriovenous malformations. A Systematic Review and meta-analysis.
World Neurosurg
January 2025
Department of Neurologic Surgery, Pontificia Universidad Javeriana, Neurosurgery Research Group.
Objective: To compare the rates of postoperative hemorrhages for aneurysms associated with brain AVM evaluating the lesion that was initially treated.
Methods: A systematic review of the literature was carried out following the PRISMA guidelines. The search was performed in PubMed, Embase and Scopus .
Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Brain mapping during resection of high-grade brain arteriovenous malformation.
Neurosurg Focus Video
January 2025
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
Eloquent brain creates a challenge when resecting brain arteriovenous malformations (bAVMs). Here the authors present their technique of using subcortical motor mapping as an adjunct to increase safety during resection of a high-grade bAVM involving somatosensory cortex as well as cortical spinal tracts and visual tracts. After a bilateral craniotomy, they use direct cortical stimulation of the left motor cortex and subcortical stimulation using a suction stimulator to dynamically map motor tracts during the resection.
View Article and Find Full Text PDFLinear Accelerator (LINAC) Radiosurgical Management of Brain Arteriovenous Malformations: An Experience From a Tertiary Care Center.
Cureus
December 2024
Radiation Oncology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Introduction: Brain arteriovenous malformations (AVM) are complex vascular pathologies with a significant risk of hemorrhage. Stereotactic radiosurgery (SRS) is an effective treatment modality for AVM, initially popularized on the Gamma Knife (Elekta AB, Stockholm, Sweden) platform, and now benefits from the modern advances in linear accelerator (LINAC)-based platforms. This study evaluates the outcomes of LINAC-based SRS/hypofractionated stereotactic radiotherapy (hFSRT) for cerebral AVMs.
View Article and Find Full Text PDFRecurrence of chronic encapsulated hematoma following cyst formation after stereotactic radiosurgery for brain arteriovenous malformations: a case report.
Chin Neurosurg J
January 2025
Department of Neurosurgery, University Hospital Cruces, Bilbao, Basque Country, Spain.
Background: Delayed radiation-induced complications after stereotactic radiosurgery (SRS) for arteriovenous malformations (AVM) have scarcely been described in the literature, and their incidence, pathophysiology, and treatment remain unclear. Additionally, the literature regarding these complications is confusing. The authors present a well-documented case report describing these late complications, adding evidence to the possible common pathophysiological mechanism underlying them, and illustrating an effective treatment modality when they occur.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!